
OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Effectiveness of Semaglutide and Tirzepatide in Overweight and Obese Adults with Type 1 Diabetes
Janet K. Snell‐Bergeon, Gurleen Kaur, D. Renner, et al.
Diabetes Technology & Therapeutics (2025) Vol. 27, Iss. 1, pp. 1-9
Closed Access | Times Cited: 4
Janet K. Snell‐Bergeon, Gurleen Kaur, D. Renner, et al.
Diabetes Technology & Therapeutics (2025) Vol. 27, Iss. 1, pp. 1-9
Closed Access | Times Cited: 4
Showing 4 citing articles:
Multifunctional incretin peptides in therapies for type 2 diabetes, obesity and associated co-morbidities
Clifford J. Bailey, Peter R. Flatt, J. Michael Conlon
Peptides (2025) Vol. 187, pp. 171380-171380
Open Access | Times Cited: 1
Clifford J. Bailey, Peter R. Flatt, J. Michael Conlon
Peptides (2025) Vol. 187, pp. 171380-171380
Open Access | Times Cited: 1
Ranting in 2025: It’s Not the Same Rant
Irl B. Hirsch
Diabetes Technology & Therapeutics (2025)
Closed Access
Irl B. Hirsch
Diabetes Technology & Therapeutics (2025)
Closed Access
Unveiling the Therapeutic Potential of the Second-Generation Incretin Analogs Semaglutide and Tirzepatide in Type 1 Diabetes and Latent Autoimmune Diabetes in Adults
Marco Infante, F Silvestri, Nathalia Padilla, et al.
Journal of Clinical Medicine (2025) Vol. 14, Iss. 4, pp. 1303-1303
Open Access
Marco Infante, F Silvestri, Nathalia Padilla, et al.
Journal of Clinical Medicine (2025) Vol. 14, Iss. 4, pp. 1303-1303
Open Access
Cardiovascular and Renal Biomarkers in Overweight and Obese Adults with Type 1 Diabetes Treated with Tirzepatide for 21 Months
Subhash Vishal Garg, Gurleen Kaur, D. Renner, et al.
Diabetes Technology & Therapeutics (2025) Vol. 27, Iss. 3, pp. 152-160
Closed Access
Subhash Vishal Garg, Gurleen Kaur, D. Renner, et al.
Diabetes Technology & Therapeutics (2025) Vol. 27, Iss. 3, pp. 152-160
Closed Access